Day: March 19, 2026

electroCore Announces Full Year 2025 Financial Results and Organizational Changes

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced full year 2025 financial results.Reported record full year of 2025 revenue of $32.0 million, an increase of approximately 27% over full year of 2024. Cash, cash equivalents, and marketable securities (“Total Cash”) of $11.6 million at December...

Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – – Phase 2 initiation for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, anticipated by end of 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2025, and recent highlights. “2025 was a pivotal year for the Company, and we anticipate another strong year ahead,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “Compelling...

Snail, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

CULVER CITY, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Recent Operational Highlights ARK Franchise Updates:ARK: Survival Evolved (“ASE”):Units sold were approximately 579,248 for the fourth quarter 2025 During the fourth quarter of 2025, average daily active users (“DAU”) was 105,468 and peak DAU was 137,404ARK: Survival Ascended (“ASA”):Units sold were approximately 691,872 for the fourth quarter 2025 During the fourth quarter of 2025, average DAU was 91,123 and peak DAU was 147,572 Launched ARK Lost Colony DLC Launched ‘ARK x Teenage Mutant Ninja...

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) – Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2025, and provided...

GrowGeneration Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP Net Loss Improved by $25.5 million; Adjusted EBITDA Improved by $8.5 million $46.1 million of Cash and Marketable Securities and no debt Board Authorizes $10 Million Share Repurchase Program 2026 Outlook: Revenue of $162 million to $168 million and Breakeven Adjusted EBITDA(1) DENVER, March 19, 2026 (GLOBE NEWSWIRE) — GrowGeneration Corp. (NASDAQ: GRWG), (“GrowGeneration,” “GrowGen” or the “Company”), one of the nation’s largest suppliers of specialty products for controlled environment agriculture (CEA), commercial cultivation, and garden centers, today announced financial results for the fourth quarter and full year ended December 31,...

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million Launched DESMODA™, the first and only FDA-approved desmopressin oral solution Licensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earnings Company expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30% Management to hold conference call today at 4:30pm ETDEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results...

Adamas Trust Declares First Quarter 2026 Common Stock Dividend of $0.23 Per Share, and Preferred Stock Dividends

Written by Customer Service on March 19, 2026. Posted in Dividend Reports And Estimates.

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — Adamas Trust, Inc. (Nasdaq: ADAM) (the “Company” or “Adamas”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.23 per share on shares of its common stock for the quarter ending March 31, 2026. The dividend will be payable on April 28, 2026 to common stockholders of record as of the close of business on March 30, 2026. In addition, the Board declared cash dividends on the Company’s 8.000% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series D Preferred Stock”), 7.875% Series E Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series E Preferred Stock”), 6.875% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series F Preferred Stock”) and 7.000% Series G Cumulative Redeemable...

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. “We are excited to enter 2026 with significant momentum as we continue to advance the development of our ProTide pipeline with the aim to deliver significantly improved treatment outcomes for patients with cancer,” said Hugh S. Griffith, NuCana’s Chief...

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Written by Customer Service on March 19, 2026. Posted in Earnings Releases And Operating Results.

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile Completed an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 development On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including completion of the NDV-01 RESCUE program Management to host a conference call and webcast today at 4:30 PM ETCORAL GABLES, Fla., March 19, 2026 (GLOBE...

Toll Brothers Opens New Model Home at Regency at Ten Trails in Black Diamond, Washington

Written by Customer Service on March 19, 2026. Posted in Public Companies.

Estelle model home debut showcases a serene cottage farmhouse design BLACK DIAMOND, Wash., March 19, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the debut of its newest Seattle-area model home at its 55+ active-adult community, Regency at Ten Trails, in Black Diamond, Washington. A grand opening event will be held on Saturday, March 28, from noon to 3 p.m. PST at 33572 Douglas Ave. SE in Black Diamond. Interested home shoppers and guests are invited to participate in a progressive tour through the stunning model homes, with light bites offered in each home.The newly unveiled Estelle model home showcases a serene cottage farmhouse design with blonde woods, inviting furnishings in linen and soft off-whites, and subtle sage green accents. This three-bedroom...

Day: March 19, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals